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Abstract
Introduction: Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind
Alzheimer’s disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and
tissue inhibitors of metalloproteinase-1 (TIMP-1) in individuals with AD dementia and cognitively healthy elderly
individuals, and to investigate their relationship with established CSF biomarkers for Alzheimer’s disease.
Methods: CSF was collected from 38 individuals with AD dementia and 34 cognitively healthy elderly individuals.
The CSF was analyzed for MMP-1, MMP-3, MMP-9, TIMP-1, b-amyloid1-42 (Ab42), total tau protein (T-tau) and
phosphorylated tau protein (P-tau). MMP/TIMP-1 ratios were calculated. APOE genotype was determined for the
participants.
Results: AD patients had higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy
individuals. In AD patients, the MMP-9/TIMP-1 ratio correlated with CSF T-tau, a marker of neurodegeneration.
Interestingly, the cognitively healthy individuals with risk markers for future AD, i.e. AD-supportive CSF biomarker
levels of T-tau, P-tau and Ab42 or the presence of the APOE ε4 allele, had higher CSF MMP-3 and MMP-9 levels
and higher CSF MMP-3/TIMP-1 ratios compared to the healthy individuals without risk markers. The CSF levels of
MMP-3 and -9 in the control group also correlated with the CSF T-tau and P-tau levels.
Conclusions: This study indicates that MMP-3 and MMP-9 might be involved in early pathogenesis of AD and that
MMPs could be associated with neuronal degeneration and formation of neurofibrillary tangles even prior to
development of overt cognitive dysfunction.
Introduction
Most cases of dementia are caused by Alzheimer’sd i s -
ease (AD), which is characterized by progressive accu-
mulation of senile plaques, containing b-amyloid (Ab),
and neurofibrillary tangles, containing hyperphosphory-
lated tau [1]. This process probably starts many years
before the typical clinical symptoms of AD appear.
However, the underlying pathologic mechanisms in AD
are still to a large extent unknown and the target of
extensive research. There is increasing evidence indicat-
ing that matrix metalloproteinases (MMPs) may play an
important but complex role in the pathology behind
neurodegenerative disorders [2-4]. MMPs are zinc- and
calcium-dependent endopeptidases, several of which are
produced by neurons and glial cells. MMPs can be
further divided into gelatinases (such as MMP-9), stro-
melysins (such as MMP-3), collagenases (such as MMP-
1) and membrane-type MMPs (MT-MMP) [2,3]. Their
activity is determined through the induction of tran-
s c r i p t i o nb yi n f l a m m a t o r ym e d i a t o r s ,t h r o u g hp o s t -
translational modification by free radicals or cytokines
and through inhibitory proteins such as tissue inhibitors
of metalloproteinases (TIMPs) [3]. The different TIMPs
often have inhibitory effects on most MMPs. However,
t h e yu s u a l l yh a v eap r e d i s p o s i t i o nt oo n eo raf e w
MMPs, for example the inhibitory effect of TIMP-1 is
primarily directed towards MMP-9 [2]. The tasks and
effects of MMPs and TIMPs are complex, and the same
MMP can have directly opposite effects on the brain
depending on the situation, location, and time point in
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include neurogenesis, angiogenesis, myelinogenesis, axo-
nal growth, and apoptosis inhibition, whereas examples
of detrimental effects are apoptosis induction, blood
brain barrier disruption and demyelination [2,3,5].
In AD, the expressions of MMP-3 and MMP-9 are
elevated in the brain and are located around neurofibril-
lary tangles and amyloid plaques [6-8]. The activity of
MMPs might be associated with the metabolism of Ab,
because Ab has been found to induce the expression of
M M P sb yb o t ha s t r o c y t e sa n dn e u r o n s[ 9 - 1 2 ] .M o r e -
over, MMP-3 and MMP-9 can cleave and degrade Ab
fibrils [8,13]. Recently, it has been suggested that MMP-
9 expression in the hippocampus is involved in Ab-
induced cognitive dysfunction [10]. These findings
together point to the need to increase our understand-
ing of the role of MMPs in AD and their relation to
other AD-related markers in vivo.
Investigation of markers in cerebrospinal fluid (CSF) is
a valuable method to study pathologic processes in the
brain. So far, the best validated CSF biomarkers for AD
are low Ab42 levels, high total tau protein (T-tau) levels
and high levels of phosphorylated tau protein (P-tau).
These biomarkers may also predict future AD dementia
with acceptable accuracy in individuals with mild cogni-
tive impairment (MCI) and they appear to be altered
already in preclinical stages [14-20]. Apart from these
biomarkers, the presence of the apolipoprotein E
(APOE) ε4 allele is another well-established risk factor
for the development of AD dementia [1].
The aim of this study was to investigate MMP-1,
MMP-3, MMP-9 and TIMP-1 in the CSF of AD patients
and healthy elderly controls, and their relation with the
established CSF biomarkers Ab42, T-tau and P-tau as
well as the APOE genotype.
Materials and methods
Study population
The study population consisted of individuals with AD
and healthy elderly individuals, who were all recruited at
the Department of Neuropsychiatry at Malmö, Skåne
University Hospital, Sweden. All individuals with AD
were patients who had been referred to the clinic due to
cognitive decline and had undergone a clinical, routine
investigation. Patients with AD fulfiling the Diagnostic
and Statistical Manual of Mental Disorders (DSM)-IIIR
criteria for dementia [21] and the criteria for probable
AD defined by the National Institute of Neurological
and Communicative Disorders and Stroke and the Alz-
heimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) [22] were eligible for the study.
The healthy elderly individuals were collected from a
clinical control group with four years of cognitive fol-
low-up and were summoned for an additional cognitive
assessment and subsequent CSF collection. There is no
clear, universal definition of the clinical characteristics
of a cognitively healthy elderly individual. In the present
study the cognitively healthy individuals were not
allowed to fulfill criteria for dementia [21] or mild cog-
nitive impairment [23] after extensive clinical and cogni-
tive assessments. In order to additionally decrease the
presence of possible early-stage cognitive impairment in
the group, a mini mental state examination (MMSE)
score of 27 points or more was required. This score is
supported by several large-scale, community-based, nor-
mative studies that have reported mean MMSE values
of 25 to 28 for individuals between 60 and 85 years of
age, depending on age and educational level [24-26]. As
these studies might have included some individuals with
minor impairments in cognitive functions, the MMSE
cut-off score in the present study was set slightly higher
than the previously reported community-based mean
values. In the present study the cognitive assessment
also included the Alzheimer’s Disease Assessment Scale
(ADAS-cog 85 points), clock test, cube copying test and
A Quick Test of cognitive speed (AQT). These results
were taken into consideration in the decision whether
dementia or MCI diagnosis criteria were fulfilled at the
time of inclusion.
The study was approved by the Regional Ethics Com-
mittee at Lund University. All participants gave their
consent to participate in the study.
Study investigations
All participants in the study had their APOE genotype
determined through blood testing. CSF collection was
performed with the patient in a sitting position. After
disposal of the first 1 ml of CSF, the next 10 ml were
obtained from the L3/L4 or L4/L5 interspaces and col-
lected in polypropylene tubes. The samples were centri-
fuged at 2,000 g at 4°C for 10 minutes to eliminate cells
and other insoluble material, and were then immediately
frozen and stored at -80°C pending biochemical ana-
lyses, without being thawed or refrozen. Cell count was
performed on the CSF samples and no sample contained
more that 500 erythrocytes/μl.
The CSF samples were analyzed for T-tau, tau protein
phosphorylated at threonine 181 (P-tau) and Ab42. In
the AD patients, CSF T-tau concentration was deter-
mined using a sandwich ELISA (Innotest® hTAU-Ag,
Innogenetics, Ghent, Belgium) specifically constructed
to measure all tau isoforms irrespective of phosphoryla-
tion status, as previously described [27]. CSF P-tau levels
were determined using sandwich ELISA (Innotest®
PHOSPHO-TAU(181P),I n n o g e n e t i c s ,G h e n t ,B e l g i u m ) .
CSF Ab1-42 levels were determined using a sandwich
ELISA (Innotest® b-amyloid (1-42), Innogenetics, Gent,
Belgium) specifically constructed to measure Ab
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st and 42
nd amino acid, as pre-
viously described [28]. In the healthy elderly individuals
analysis was performed with xMAP technology using
the INNO-BIA AlzBio3 kit (Innogenetics, Ghent, Bel-
gium) and the same batch of reagents [29]. Results from
the Luminex xMAP system were converted to ELISA
levels based on previously published conversion factors
[29]. The results are presented in ng/l.
The CSF MMP-1, MMP-3, MMP-9 and TIMP-1 levels
were measured using commercially available immunoas-
says according to the instructions provided by the man-
ufacturers ‘Meso Scale Discovery’ (Gaithersburg, MD,
USA) and ‘R&D System’ (Minneapolis, MN, USA),
respectively. For the MMP assays a 12-point standard
curve was used. The detection limit of the assay was
0.008 ng/ml of human recombinant MMP-1, 0.04 ng/ml
of human recombinant MMP-3, 0.24 ng/ml of human
recombinant MMP-9, and 0.031 ng/ml of human
recombinant TIMP-1 with an inter-assay variation of
less than 10%. The results are presented in ng/ml. The
ratios of MMP-1/TIMP-1, MMP-3/TIMP-1 and MMP-
9/TIMP-1 were additionally calculated.
For subgroup analyses, the healthy elderly individuals
were divided according to deviant CSF biomarker levels
and according to presence of the APOE ε4 allele, which
are established risk markers for future dementia. Cut-off
levels to define deviant CSF biomarker levels were deter-
mined at a CSF Ab42/P-tau ratio of less than 6.5 com-
bined with CSF T-tau levels of more than 350 ng/l. These
cut-off levels were chosen because this combination has
predicted future AD with a sensitivity of 95% and a specifi-
city of 87% in a large MCI study population [15].
Statistics
Statistical analysis was performed using the PASW soft-
ware (former SPSS software, version 17.0.1 for Win-
dows, SPSS Inc., Chicago, IL, USA). Non-parametric
tests were used because normal distribution could not
be assumed in the groups. Spearman rank correlation
coefficient (rs) was used to test the degree of correlation
between CSF biomarkers, MMP and TIMP-1 levels as
well as the influence of age. Mann-Whitney U test was
used when one of the variables was dichotomized
(group comparisons, presence of deviant CSF biomarker
levels, APOE ε4 allele carrier and gender). Fisher’s Exact
Test was used if both variables were dichotomized
(group comparisons of APOE ε4 allele carrier and gen-
der). The level of significance was set to P < 0.05.
Results
Participant characteristics
The characteristics for the AD group and the group of
healthy elderly individuals are presented in Table 1. The
38 AD patients had significantly higher CSF T-tau and
CSF P-tau levels, lower CSF Ab42 levels, lower MMSE
scores and higher presence of the APOE ε4a l l e l ec o m -
pared with the 34 healthy elderly individuals. No differ-
ence in age or gender was observed between the groups.
CSF MMPs and TIMP-1 levels in the AD patients
The CSF MMP-9/TIMP-1 ratios were significantly
higher and the CSF TIMP-1 levels were significantly
lower in the AD patients compared with the healthy
elderly individuals (P < 0.05; Table 1). Moreover,
increased CSF T-tau levels correlated with high CSF
MMP-9/TIMP-1 ratios (rs = 0.448, P < 0.01) and MMP-
3/TIMP-1 ratios (rs = 0.351, P < 0.05) in the AD
patients (Figures 1 and 2). APOE genotype, age and gen-
der did not correlate with the CSF MMPs and TIMP-1
levels or with the CSF MMP/TIMP-1 ratio.
CSF MMPs and TIMP-1 levels in the healthy elderly
individuals
In the group of healthy elderly individuals, both higher
levels of CSF MMP-9 and MMP-3 correlated with
higher CSF T-tau levels (rs =0 . 4 9 4 ,P <0 . 0 1a n dr s =
0.557, P < 0.001) and P-tau levels (rs = 0.435, P <0 . 0 5
and rs = 0.554, P < 0.001; Figures 3 and 4). As seen in
the AD participants, higher CSF MMP-3/TIMP-1 ratio
correlated with higher CSF T-tau levels (rs = 0.352, P <
0.05) but in healthy elderly individuals the ratio also
correlated with higher CSF P-tau levels (rs = 0.376, P <
0.05).
The seven healthy elderly individuals with an AD-sup-
portive CSF biomarker pattern (CSF Ab42/P-tau ratio
<6.5 combined with CSF T-tau >350 ng/l [15]) had sig-
nificantly higher levels of CSF MMP-9 (z = -2.37, P <
0.05; Figure 5) compared with the other 27 healthy
elderly individuals. In addition, the nine APOE ε4a l l e l e
carriers had higher levels of CSF MMP-9 (z = -2.13, P <
0.05; Figure 6) and CSF MMP-3 (z = -2.23, P <0 . 0 5 )
compared with the 25 non-carriers.
Discussion
I nt h ep r e s e n ts t u d yw es h o wt h a tA Dp a t i e n t sh a v ea
higher MMP-9/TIMP-1 ratio and a lower TIMP-1 level
in CSF compared with cognitively healthy elderly indivi-
duals and that the MMP-9/TIMP-1 ratio in AD patients
correlates with CSF T-tau, a marker of neuronal degen-
eration. In the group of healthy elderly individuals we
observed that the individuals with risk markers for pos-
sible future AD, that is AD-supportive CSF biomarkers
(tau and Ab42) or presence of the APOE ε4 allele, have
higher CSF MMP-3 and MMP-9 levels and a higher
CSF MMP-3/TIMP-1 ratio compared with the indivi-
duals without risk markers. In addition, the CSF MMP-
3 and MMP-9 levels correlate with the CSF T-tau and
P-tau levels in the elderly controls.
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elevated expression of MMP-3 and MMP-9 that have
been observed in brain tissue of patients with estab-
lished AD [7,8]. In particular, MMP-9 has been
observed to have elevated expression in the hippocam-
pus, around senile plaques and neurofibrillary tangles
and in vessel walls [6,8], whereas MMP-3 is expressed
primarily around plaques in the parietal lobes [7].
Hence, the expression of these MMPs is located in the
brain regions and adjacent to histologic features that are
closely related to AD. However, not all types of MMPs
seem to be associated with AD pathogeneses. In the pre-
sent study, MMP-1 (a collagenase) does not correlate
with AD diagnosis or risk factors for future development
of AD, a finding that is supported by a previous study
that investigated the levels of different MMPs in plasma
of AD patients [30].
The increased levels of several MMPs in the CSF of
individuals with increased risk for AD, as observed in
the current study, could be explained by several
Table 1 Characteristics for the AD group and the group of healthy elderly individuals
AD HC Group difference
Demographics
Number 38 34
Age 76 ± 7 77 ± 8 ns
Gender (F/M) 23/15 24/10 ns
MMSE 19 ± 5 29 ± 1 P <1 0
-12
APOE ε4 heterozygote (homozygote) 63% (13%) 24% (3%) P <1 0
-4
CSF**
Ab42 307 ± 91 647 ± 166 P <1 0
-11
T-tau 938 ± 542 399 ± 194 P <1 0
-8
P-tau 106 ± 55* 64 ± 28 P <1 0
-4
MMP-1 0.024 ± 0.016 0.021 ± 0.01 ns
MMP-3 0.716 ± 0.35 0.700 ± 0.36 ns
MMP-9 0.902 ± 0.39 0.859 ± 0.35 ns
TIMP-1 0.035 ± 11.7 0.041 ± 13.0 P < 0.05
MMP-1/TIMP-1 0.697 ± 0.35 0.564 ± 0.25 ns
MMP-3/TIMP-1 21.1 ± 9.7 18.1 ± 9.8 ns
MMP-9/TIMP-1 26.9 ± 11.9 22.7 ± 11.8 P < 0.05
Ab42, b-amyloid1-42; AD, Alzheimer’s disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; F, female; HC, healthy controls; M, male; MMP, matrix
metalloproteinase; MMSE, mini mental state examination; TIMP, tissue inhibitor of metalloproteinase.
* n = 28. ** Levels are in ng/l for Ab42, T-tau and P-tau and in ng/ml for the MMPs and TIMP-1.
Figure 1 Scatter plot of CSF MMP-9/TIMP-1 ratio and CSF T-tau
levels in patients with Alzheimer’s disease. CSF T-tau levels are
presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix
metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
Figure 2 Scatter plot of CSF MMP-3/TIMP-1 ratio and CSF T-tau
levels in patients with Alzheimer’s disease. CSF T-tau levels are
presented in ng/l. CSF, cerebrospinal fluid; MMP, matrix
metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
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general, the CSF levels of MMPs are influenced by the
production of MMPs by neurons and glial cells, the
release of MMPs by inflammatory cells and extravasa-
tion of MMPs from peripheral blood. All of these
mechanisms could be influenced by AD pathology. For
example, increased levels of plasma MMP-9 have been
observed in AD patients [30,31]. Both in vitro and in
vivo studies have further suggested that the production
of MMP-3 and MMP-9 are induced by AD-related pro-
t e i n ss u c ha sA b1-40 and Ab1-42 [ 9 - 1 2 ] .F i n a l l y ,p r o -
inflammatory molecules, which exist in and contribute
to the AD neurodegenerative process, are inducers of
MMP-3 and MMP-9 expression both locally in
the brain and in inflammatory cells recruited from the
peripheral circulation [2,12,32].
In the current study, CSF TIMP-1 levels were
decreased and the MMP-9/TIMP-1 ratio was higher in
AD patients when compared with healthy individuals.
This could suggest the presence of an imbalance
between MMP-9 and TIMP-1 in AD patients, which
leads to a predominant MMP-9 activity in the brain.
Figure 3 Scatter plot of CSF MMP-9 levels and CSF T-tau levels
in the cognitively healthy elderly individuals. CSF MMP-9 levels
are presented in ng/ml and CSF T-tau levels are presented in ng/l.
CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.
Figure 4 Scatter plot of CSF MMP-9 levels and CSF P-tau levels
in the cognitively healthy elderly individuals. CSF MMP-9 levels
are presented in ng/ml and CSF P-tau levels are presented in ng/l.
CSF, cerebrospinal fluid; MMP, matrix metalloproteinase.
Figure 5 Error plot of difference in CSF MMP-9 levels between
the cognitively healthy elderly individuals with AD-indicative
CSF biomarker levels (n = 7) compared with those with
unaffected CSF biomarker levels (n = 27). CSF MMP-9 levels are
presented in ng/ml. AD, Alzheimer’s disease; CSF, cerebrospinal fluid;
MMP, matrix metalloproteinase.
Figure 6 Error plot of difference in MMP-9 levels between
cognitively healthy elderly individuals with at least one APOE
ε4 allele (n = 9) compared with those without the allele (n =
25). CSF MMP-9 levels are presented in ng/ml. CSF, cerebrospinal
fluid; MMP, matrix metalloproteinase.
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between high levels of CSF tau and high MMP-9/TIMP-
1 ratios in the AD group.
A number of actions of MMPs and TIMPs, apart from
the inflammatory response, have been closely linked to
AD pathology. For example, MMP-9 has been shown to
be able to cleave and degrade Ab40 and aggregated
Ab42 fibrils both in vitro and in vivo [4,8,13]. In light of
these possible AD protecting effects of MMP-9, it has
been suggested that the increased MMP-9 levels
observed in AD might be of the inactive form [2,8,12].
This could explain why Ab still accumulates into pla-
ques despite the increased levels of certain MMPs. It
can further be noted that a specific MMP or TIMP has
diverse effects on brain tissue depending on the situa-
tion, location and point in time of its expression and
release [2,3]. An alternative interpretation of the
increased MMP levels in AD could be that the detri-
mental activity of MMPs, which leads to brain damage,
exceeds its beneficial brain protective activity. Interest-
ingly, Mizoguchi and colleagues [10] have recently
shown that Ab-induced neurotoxicity in vitro as well as
cognitive impairment in vivo is significantly alleviated by
treatment with MMP inhibitors and significantly
reduced in MMP-9 homozygous knockout mice, indicat-
ing that MMP-9 expression in the hippocampus might
be involved in Ab-induced cognitive dysfunction. More-
over, another study has shown increased activity of
MMP-9 after stimulation with neurotoxic kainate in
organotypic hippocampal cultures and reduced neuronal
cell death after inhibition of MMP-9 [33]. Furthermore,
in the same study, authors have shown that MMP-9
induces neuron death in vitro.T o g e t h e rt h e s er e s u l t s
indicate that MMP-9 might be involved in both Ab-
induced neuronal dysfunction as well as in excitotoxic
cell death in the hippocampus.
The progressive neurodegeneration in AD precedes
the decline in cognitive function and dementia diagnosis
by decades [1]. The CSF biomarkers tau and Ab are
today well validated markers for AD pathology and they
are associated with development of AD dementia in
individuals with mild cognitive impairment [15-17].
Increasing evidence suggests that these CSF biomarkers
indicate the presence of AD pathology also prior to the
cognitive impairment, that is in cognitively unaffected
elderly individuals [18-20,34,35]. In the present study
certain MMPs and TIMP-1 levels were related to these
CSF biomarkers. Interestingly, MMP-3 and MMP-9
were elevated in healthy elderly individuals with CSF
biomarker levels implying an increased risk of future
development of AD. In addition, increased CSF MMP-3
and MMP-9 levels in healthy elderly individuals corre-
lated with the CSF levels of T-tau and P-tau. In con-
trast, no correlations were seen with CSF levels of Ab42,
which is surprising due to the possible relation between
MMP-9 and amyloid pathology seen in animal models
and the fact that Ab42 is thought to be the first biomar-
k e rt ob ec h a n g e di np r e c l i n i c a lA D[ 3 6 ] .H o w e v e r ,a
recent neuropathologic study reports that elevated
MMP-9 activity correlates with Braak stage but not with
NIA-Reagan diagnosis [37]. The major difference
between Braak stage and the NIA-Reagan criteria is that
the former only evaluates presence of tau pathology,
whereas the latter evaluates presence of both tau and
amyloid pathology [38,39]. In summary, our findings
suggest that MMPs may be associated with AD patho-
logy as well as with the presence of neuronal degenera-
tion and formation of neurofibrillary tangles already in
cognitively unaffected individuals.
Healthy elderly individuals with at least one APOE ε4
allele exhibit a three-fold increased risk of developing
AD later on and are thereby more likely to have
ongoing progressive neurodegenerative processes in the
brain [1]. The higher CSF MMP-3 and MMP-9 levels
seen in the healthy elderly individuals with at least one
APOE ε4 allele in the present study, further supports a
probable relation between MMPs and the presence of
preclinical AD pathology. In alignment with this finding,
Saarela and colleagues [40] have previously shown that
t h ep r e s e n c eo ft h eAPOE ε4 allele together with a cer-
tain MMP-3 polymorphism increases the risk for devel-
oping AD in cognitively unaffected elderly individuals
more than the presence of APOE ε4 allele alone [40].
A limitation of the study might be that CSF T-tau,
P-tau and Ab42 levels were measured with different
methods in the AD patients compared with the healthy
elderly individuals. The aim of the present study, how-
ever, was not to make group comparisons of these
three CSF biomarkers. Instead, they were used to
employ correlations with other markers within each
group and to define ‘individuals within the control
group with increased risk for future AD’.T h eg r o u p
difference in the CSF analysis method should therefore
not influence the findings of the study. Moreover, it
should be stated that the present data do not suggest
MMP and TIMP-1 levels to be used for diagnostic dis-
crimination. For this purpose, the overlap between the
groups are too great and the discriminatory ability too
low compared with currently accepted biomarkers
such as CSF T-tau, P-tau and Ab42. Similarly, the spe-
cificity of MMP and TIMP-1 levels to AD can not be
evaluated in the present study because it was not
designed to study other dementia disorders than AD.
Another limitation could be that extensive neuropsy-
chological testing was not performed on the control
individuals and that cognitive follow-up currently only
exists up to the time of inclusion. However, the cogni-
tive assessments performed at and prior to the
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ment should have minimized the presence of early-
stage cognitive impairment in the control group.
Despite these efforts complete absence of preclinical
cognitive impairment in the group can not be ensured.
Conclusions
In the present study, the CSF MMP-9/TIMP-1 ratio was
increased in AD patients, and correlated with the neuro-
nal degeneration marker tau. More importantly, cogni-
tively healthy elderly individuals, with increased risk of
developing AD in the future, had elevated CSF MMP-3
and MMP-9 levels and an increased CSF MMP-3/
TIMP-1 ratio, indicating that MMP-3 and MMP-9
might be involved in early pathogenesis of AD. More-
over, CSF levels of MMP-3 and MMP-9 correlated with
both CSF T-tau and P-tau in elderly controls, suggesting
that MMPs could be associated with neuronal degenera-
tion and/or the formation of P-tau-containing neuro-
fibrillary tangles in individuals who have not yet
developed any overt cognitive dysfunction.
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